Supplementary Figure 1 . Two dimensional clustering enables the distinction of unique clones and the reconstruction of a phylogenetic tree. The phylogenetic relationships were inferred using a serial implementation of 2 dimensional clustering between every two samples in each patient. For each patient, the inferred patterns of clonal evolution are depicted (as in Figures 1-3) , and representative examples of the 2 dimensional clustering are shown. The individual clones are highlighted with a circle, in addition to candidate driver mutations in each clone.
Supplementary Figure 2. Complete mutation annotation overlaid on the phylogenetic tree.
For each patient, the mutations are assigned to each clone based on the phylogenetic inference resulting from the serial implementation of 2 dimensional clustering between every 2 samples. Likely candidate drivers are highlighted in pink.
Supplementary Figure 3.
A. IGV screenshot of the BTK mutation in Patient 4 CLL cells at the time of relapse. The BTK C481S mutation can be readily detected by both WES of relapsed leukemia cells (top), as well as by matched RNA-sequencing (bottom). Sequence is shown in reverse orientation. These data show a mutation that converts a cysteine at position 481 (TGC) to a serine (TCC). B. Single cell expression of wildtype and mutant PLCG2 (at T3636A, T3636G, G3191C, C2334T sites) from cells collected at the of ibrutinib relapse (timepoint (TP) 5) of Patient 1. All data were generated by targeted mutation amplification of single cells on microfluidic chips (Fluidigm Biomark system). Log 2 transformed expression of mutant vs wildtype PLCG2 alleles are plotted, with each dot representing one single cell. Cells identified to be PLCG2 wild-type are denoted in blue, while those inferred to be PLCG2 mutant are red. Cells with ambiguous mutation calls are denoted in grey. Schematic of the minimal common region of loss of chromosome 8p in CLLs, to which FISH probes were designed. B. SNP array analysis of Patients 2, 3 and 5 and other CLLs from DFCI (CLL1-CLL5) to which deletion in chromosome 8p was detected. C. Changes in TRAIL-R (DR4) expression in two CLL patients who developed ibrutinib resistance (Pt 2 and 3) with del8p. After gating on CLL cells, lower TRAIL-R expression was noted at time of ibrutinib resistance (blue) compared to prior to treatment initiation (orange). D. left-Percentage of nuclei scored with 8p deletion following hybridization to the 8p FISH probe across nuclei from CLL samples, previously characterized by karyotyping as monosomy 8 or deletion of 8p by the BWH Clinical Cytogenetics lab as positive (n=5) or negative (n=5) for deletion in chromosome 8p. For each case, 100 nuclei were scored. The maximum background (i.e. a single 8p21.3 signal) in negative control specimens was 5%. Based on this data the threshold for considering a sample as positive for del(8p) by FISH is 9.4% (mean of negatives + 3SD). Right-Confirmation of del(8p) status of 9 'negative' and 6 'positive' samples (corresponding to the samples analyzed in Figure  5C ) through del(8p) FISH of fixed cell pellets. E. Visualization of the consistent elevated relative gene expression of TRAIL across probesets in peripheral blood of normal donors compared to lymph nodes, as previously reported 22 . F. Comparable levels of TRAIL in plasma of CLL patients with ibrutinib resistance with del(8p) (Pts 1, 2, 3 Tables  Supplementary Table 1 
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